Log in

Coherus Biosciences Stock Forecast, Price & News

+0.59 (+3.47 %)
(As of 10/23/2020 12:00 AM ET)
Today's Range
Now: $17.59
50-Day Range
MA: $18.28
52-Week Range
Now: $17.59
Volume871,750 shs
Average Volume1.31 million shs
Market Capitalization$1.26 billion
P/E Ratio7.52
Dividend YieldN/A
Coherus BioSciences, Inc., a commercial-stage biotherapeutics company, focuses on the biosimilar market worldwide. It markets UDENYCA, a long-acting granulocyte-colony stimulating factor, which stimulates production of granulocytes in order to promote the body's ability to fight infections. The company sells UDENYCA in the United States. Its clinical-stage product candidates include immunology, anti-tumor necrosis factor biosimilar candidates, CHS-1420 for adalimumab and CHS-0214 for etanercept, which has completed Phase III clinical programs; ophthalmology biosimilar candidates, CHS-3351 for ranibizumab and CHS-2020 for aflibercept that is in preclinical development; and CHS-131, small molecule therapeutic candidate and other metabolic conditions. Coherus BioSciences, Inc. has collaboration and license agreements with Daiichi Sankyo Company, Limited; Baxalta Incorporated; Baxalta US Inc.; Baxalta GmbH; and Selexis SA. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Read More
Coherus Biosciences logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.43 out of 5 stars

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:CHRS



Sales & Book Value

Annual Sales$356.07 million
Cash Flow$1.37 per share
Book Value$1.50 per share


Net Income$89.83 million


Market Cap$1.26 billion
Next Earnings Date11/5/2020 (Confirmed)
+0.59 (+3.47 %)
(As of 10/23/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CHRS News and Ratings via Email

Sign-up to receive the latest news and ratings for CHRS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Coherus Biosciences (NASDAQ:CHRS) Frequently Asked Questions

How has Coherus Biosciences' stock price been impacted by Coronavirus?

Coherus Biosciences' stock was trading at $15.87 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CHRS stock has increased by 10.8% and is now trading at $17.59.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Coherus Biosciences?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Coherus Biosciences in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Coherus Biosciences

When is Coherus Biosciences' next earnings date?

Coherus Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Coherus Biosciences

How can I listen to Coherus Biosciences' earnings call?

Coherus Biosciences will be holding an earnings conference call on Thursday, November 5th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Coherus Biosciences' earnings last quarter?

Coherus Biosciences Inc (NASDAQ:CHRS) announced its quarterly earnings results on Thursday, August, 6th. The biotechnology company reported $0.70 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.26 by $0.44. The biotechnology company had revenue of $135.67 million for the quarter, compared to analyst estimates of $100.33 million. Coherus Biosciences had a return on equity of 139.51% and a net margin of 37.11%.
View Coherus Biosciences' earnings history

What price target have analysts set for CHRS?

8 brokers have issued 1-year price objectives for Coherus Biosciences' stock. Their forecasts range from $20.00 to $43.00. On average, they expect Coherus Biosciences' share price to reach $30.00 in the next year. This suggests a possible upside of 70.6% from the stock's current price.
View analysts' price targets for Coherus Biosciences

Who are some of Coherus Biosciences' key competitors?

What other stocks do shareholders of Coherus Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Coherus Biosciences investors own include Halozyme Therapeutics (HALO), Chembio Diagnostics (CEMI), Exelixis (EXEL), Heron Therapeutics (HRTX), TG Therapeutics (TGTX), Intelsat (I), Idera Pharmaceuticals (IDRA), Immunomedics (IMMU), Sangamo Therapeutics (SGMO) and Viking Therapeutics (VKTX).

Who are Coherus Biosciences' key executives?

Coherus Biosciences' management team includes the following people:
  • Mr. Dennis M. Lanfear, Chairman, Pres & CEO (Age 64)
  • Dr. Jean-Frédéric Viret, Chief Financial Officer (Age 53)
  • Dr. Peter K. Watler, Chief Technical Officer (Age 57)
  • Dr. V. Bryan Lawlis Jr., Science Director, Director & Member of Supervisory Board (Age 67)
  • Mr. Vincent R. Anicetti, Chief Operating Officer (Age 64)

What is Coherus Biosciences' stock symbol?

Coherus Biosciences trades on the NASDAQ under the ticker symbol "CHRS."

Who are Coherus Biosciences' major shareholders?

Coherus Biosciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include Candriam Luxembourg S.C.A. (0.99%), Peregrine Capital Management LLC (0.73%), Foundry Partners LLC (0.08%), State of Alaska Department of Revenue (0.08%), Assenagon Asset Management S.A. (0.07%) and Ziegler Capital Management LLC (0.05%). Company insiders that own Coherus Biosciences stock include Dennis M Lanfear, James Healy, Jean-Frederic Viret, Mary T Szela, Mats Wahlstrom and Vincent R Anicetti.
View institutional ownership trends for Coherus Biosciences

Which major investors are selling Coherus Biosciences stock?

CHRS stock was sold by a variety of institutional investors in the last quarter, including Cadence Capital Management LLC, Ziegler Capital Management LLC, Assenagon Asset Management S.A., and Foundry Partners LLC. Company insiders that have sold Coherus Biosciences company stock in the last year include Dennis M Lanfear, Jean-Frederic Viret, Mary T Szela, Mats Wahlstrom, and Vincent R Anicetti.
View insider buying and selling activity for Coherus Biosciences

Which major investors are buying Coherus Biosciences stock?

CHRS stock was bought by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Candriam Luxembourg S.C.A., Louisiana State Employees Retirement System, Pacer Advisors Inc., Standard Life Aberdeen plc, Campbell & CO Investment Adviser LLC, Nisa Investment Advisors LLC, and DNB Asset Management AS.
View insider buying and selling activity for Coherus Biosciences

How do I buy shares of Coherus Biosciences?

Shares of CHRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Coherus Biosciences' stock price today?

One share of CHRS stock can currently be purchased for approximately $17.59.

How big of a company is Coherus Biosciences?

Coherus Biosciences has a market capitalization of $1.26 billion and generates $356.07 million in revenue each year. The biotechnology company earns $89.83 million in net income (profit) each year or $1.23 on an earnings per share basis. Coherus Biosciences employs 232 workers across the globe.

What is Coherus Biosciences' official website?

The official website for Coherus Biosciences is www.coherus.com.

How can I contact Coherus Biosciences?

Coherus Biosciences' mailing address is 333 TWIN DOLPHIN DRIVE SUITE 600, REDWOOD CITY CA, 94065. The biotechnology company can be reached via phone at 650-649-3530 or via email at [email protected]

This page was last updated on 10/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.